Thursday, December 15, 2022 11:40:49 AM
8.39% 0.00% 0 2022-12-15 11:00:03
8.39% 0.00% 0 2022-12-15 10:45:03
8.39% 0.00% 0 2022-12-15 10:30:03
8.39% 0.00% 0 2022-12-15 10:15:04
8.39% 0.00% 0 2022-12-15 10:00:03
8.39% 0.00% 0 2022-12-15 09:45:04
8.39% 0.00% 0 2022-12-15 09:30:03
8.39% 0.00% 0 2022-12-15 09:15:04
8.39% 0.00% 0 2022-12-15 09:00:04
8.39% 0.00% 0 2022-12-15 08:45:03
8.39% 0.00% 0 2022-12-15 08:30:03
8.39% 0.00% 0 2022-12-15 08:15:03
8.39% 0.00% 0 2022-12-15 08:00:04
8.39% 0.00% 0 2022-12-14 17:45:04
8.39% 0.00% 0 2022-12-14 17:30:03
8.39% -4.57% 2000 2022-12-14 17:15:04
8.39% -4.57% 6000 2022-12-14 17:00:03
8.39% -4.57% 6000 2022-12-14 16:45:03
8.39% -4.57% 10000 2022-12-14 16:30:04
8.39% -4.57% 10000 2022-12-14 16:15:03
8.39% -4.57% 10000
Recent SRZN News
- Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis • GlobeNewswire Inc. • 04/03/2024 12:40:07 PM
- Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043 • GlobeNewswire Inc. • 04/01/2024 12:30:54 PM
- Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/01/2024 12:30:11 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/07/2024 11:16:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 11:10:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/22/2024 10:24:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 01:41:46 PM
- Surrozen Provides Corporate Update on Clinical Programs • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 02:26:15 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/13/2023 10:21:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 10:14:53 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/11/2023 09:11:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:08:09 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/08/2023 09:27:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:17:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:09:25 PM
- Surrozen Provides Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/08/2023 09:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/24/2023 08:23:12 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/24/2023 08:18:09 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/13/2023 08:51:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 08:19:20 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2023 09:17:42 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/09/2023 08:39:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:25:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 08:16:22 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM